Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Drug Profile

Olodaterol/tiotropium bromide - Boehringer Ingelheim

Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; Stiolto; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva Respimat

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Oct 2018 The US FDA approves sNDA for inclusion of chronic bronchitis and emphysema in treatment of patients with Chronic obstructive pulmonary disease
  • 18 Jul 2018 Registered for Chronic obstructive pulmonary disease in China (Inhalation)
  • 18 May 2018 Efficacy and adverse events data from a phase III (VESTUO study) trial in Chronic obstructive pulmonary disease (COPD) presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top